Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — J.P. Morgan Healthcare Conference 2021
33 slides from Revvity's conference presentation, Jan 11, 2021
Slide 1: J.P. Morgan Healthcare Conference
Exhibit 99.1 J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2021 1Exhibit 99.1 J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2021 1
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains forward-looking statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our
Slide 3: What You'll Hear Today
WHAT YOU’LL HEAR TODAY … Positioning Us for Future Success Continued Progress against Our Strategic Foundation … COVID-19 response validates our foundational efforts RECENT FOCUS VALUE CREATION FRAMEWORK PORTFOLIO Enhanced Diagnostics brand Add Meaningful TRANSFORMATION Scale bolsters existing posit
Slide 4: Portfolio Transformation
PORTFOLIO TRANSFORMATION þ Positioned for more stable Attractive >80% of 2020 revenue from END MARKETS MSD+ growth Diagnostics and Life Sciences þ Improved >70% of portfolio in consumables, Supporting more consistent PRODUCT MIX services, & software and linear revenue þ Increased 33% of revenue in R
Slide 5: Strengthened Capabilities: Two Recent Acquisitions in Adjacent Markets
STRENGTHENED CAPABILITIES: TWO RECENT ACQUISITIONS IN ADJACENT MARKETS þ Attractive END MARKETS ~$800M capital deployed in new adjacent markets growing HSD þ Improved PRODUCT MIX þ Closed December 23 Closing 1H21 Increased GEOGRAPHIC REACH $3B TAM >$1B TAM Gene Editing Latent TB Diagnostics þ Streng
Slide 6: Organizational Alignment
ORGANIZATIONAL ALIGNMENT Unified R&D Positioned 2K+ One to Drive Product Vitality & Decrease Time Person Global R&D R&D Team to Market Global Commercial Unified 6K+ Resources Localized to Go-to- the Customer across a Global Commercial Market Resources Broad Portfolio Centralized Operations 3K+ Globa
Slide 7: Progress on Our Strategic Priorities
PROGRESS ON OUR STRATEGIC PRIORITIES STRONG ENHANCED FOCUSED TRANSFORMATIVE TALENT & CUSTOMER OPERATIONAL INNOVATION CULTURE EXPERIENCE EXCELLENCE ✓ Strong employee ✓ Achieved 3 FDA EUAs ✓ Unified and ✓ Improved quote-to- retention (~8% voluntary and 13 CE-marks for new personalized account delivery
Slide 8: PerkinElmer Today
PERKINELMER TODAY Diagnostics ~75% ~25% (Dx) Consumables, Services, Software Instruments ~30% ~40% $3.8B Asia Americas 2020e revenue* ~30% Discovery & Europe Analytical Solutions (DAS) † 2020 Performance Adj. Gross Adj. Op Org. Rev Adj. EPS + + + 29% 500 bps 1000 bps 90 % Margin Margin Growth Growth
Slide 9: Driving Value Creation Across the Portfolio
DRIVING VALUE CREATION ACROSS THE PORTFOLIO VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DISCOVERY AND DIAGNOSTICS ANALYTICAL SOLUTIONS Add Meaningful Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Eve
Slide 10: Transformative Diagnostics
TRANSFORMATIVE DIAGNOSTICS VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful 1 Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Event Strengthen Core Confidence in December 2020
Slide 11: Most Sensitive SARS-CoV-2 Detection Assay
MOST SENSITIVE SARS-COV-2 DETECTION ASSAY Scaling Molecular 25M+ $350M+ Tests Shipped 2020e Revenue Lowest Limit-of-Detection Available on the Market 90x better than industry average New Coronavirus Nucleic Acid Detection Kit Note: FDA SARS-CoV-2 Reference Panel Comparative Data (link) 11MOST SENSIT
Slide 12: Best-in-Class Extraction Portfolio Delivered at Scale
BEST-IN-CLASS EXTRACTION PORTFOLIO DELIVERED AT SCALE Superior Global Performance Scale Leading >1,000 sensitivity chemagic 360 best-in-class magnetic placements in 2020 bead yield Fully- ~75 million automated chemagic tests TM high-throughput chemagic 360 and chemagic kits sold in 2020 processing A
Slide 13: Differentiated SARS-CoV-2 Serology Solutions
DIFFERENTIATED SARS-COV-2 SEROLOGY SOLUTIONS Combines fully-automated Leveraging newborn screening with Capabilities best-in-class antibody assay technology Easy-to-use sample collection Novel with dried blood spot cards enables point-of-care, Sample Type decentralized sample collection GSP®/DELFIA®
Slide 14: Complete Workflow Solution Enabled by Unified R&D Team
COMPLETE WORKFLOW SOLUTION ENABLED BY UNIFIED R&D TEAM Novel Innovation End-to-end automated workstation to streamline testing workflows and eliminate errors Flexibility to scale to meet current COVID-19 and future infectious disease testing needs, with best-in-class throughput up to 10K samples / d
Slide 15: Record Performance
RECORD PERFORMANCE REVENUE INSTALLED BASE BRAND Meaningful ~1,750 >$1B Diagnostics new instruments placed Brand Recognition 2020e COVID revenue across the portfolio 15RECORD PERFORMANCE REVENUE INSTALLED BASE BRAND Meaningful ~1,750 >$1B Diagnostics new instruments placed Brand Recognition 2020e COV
Slide 16: Diagnostics Deep Dive
DIAGNOSTICS DEEP DIVE VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Event Strengthen Core 2 Confidence in December 2020 Righ
Slide 17: Immunodiagnostics at a Glance
IMMUNODIAGNOSTICS AT A GLANCE Infectious Highlighted Autoimmune Allergy Other Diseases Portfolio Capabilities & Differentiators #1 #3 Leading Expanded Autoimmune Allergy Emerging Virus Neurodegenerative Testing Testing Menu Testing HOW WE WIN ~$1.0B ~85% 2020e Revenue Recurring Revenue ✓ Extensive m
Slide 18: Immunodiagnostics Value Creation Focus: Automation
IMMUNODIAGNOSTICS VALUE CREATION FOCUS Strengthen Share gain opportunities with random access Core Right to Win Automation instruments for any throughput Maximize Growth Accelerators SuperFlex™ (CE-IVD) Accentis Add Meaningful Scale Lower / Point of Care Higher Throughput 18IMMUNODIAGNOSTICS VALUE C
Slide 19: Immunodiagnostics Value Creation Focus: Infectious Disease
IMMUNODIAGNOSTICS VALUE CREATION FOCUS Strengthen Infectious Scaling menu with further expansion into Core Right to Win infectious disease Disease Maximize Growth Accelerators Add TM PKamp Respiratory SARS-CoV-2 Anti-SARS-CoV-2 QuantiVac ELISA (IgG) Meaningful Scale RT-PCR Panel Assay (CE-IVD) (CE-I
Slide 20: Applied Genomics at a Glance
APPLIED GENOMICS AT A GLANCE Liquid Nucleic NGS Handling / Highlighted Acid Sample Prep Automation Isolation Portfolio Capabilities & Differentiators #1 Platform- Top-3 Automated Full Suite of Agnostic RNA/DNA Reagents Automation Provider Extraction HOW WE WIN ~65% ~$550M 2020e Revenue Recurring Rev
Slide 21: Applied Genomics Value Creation Focus: 3Ds
APPLIED GENOMICS VALUE CREATION FOCUS Strengthen Differentiating Detection, Decentralization, Core Right to Win and Digitalization through “3Ds” Driving unparalleled Supporting Increasing Digital solutions Detection across the Decentralization to to support data and drive workflow expand our SAM act
Slide 22: Applied Genomics Value Creation Focus: Emerging Technologies
APPLIED GENOMICS VALUE CREATION FOCUS Driving innovation through internal R&D Strengthen Emerging efforts as well as investments Core Right to Win Technologies in promising start-ups Maximize Growth Accelerators Add PKeye Honeycomb HIVE Cell Drive Meaningful Scale (In development – launch in 2021) M
Slide 23: Reproductive Health at a Glance
REPRODUCTIVE HEALTH AT A GLANCE Prenatal Newborn Rare Disease (Biochemistry (Immunoassay, Highlighted Testing & NIPT) MS & NGS) Portfolio Capabilities & Differentiators #1 in Prenatal #1 in Newborn Partner of Choice (Biochemical) Screening for Pharma HOW WE WIN ~$450M ~95% 2020e Revenue Recurring Re
Slide 24: Reproductive Health Value Creation Focus: Technology Breadth
REPRODUCTIVE HEALTH VALUE CREATION FOCUS Solidifying market leadership and Strengthen Technology customer loyalty with new molecular Core Right to Win Breadth solutions ✓ Immunoassays Maximize Growth Accelerators ✓ Mass Spec SMA SCID XLA ❑ Molecular TM ✓ EONIS PCR Reagent Kits Add (CE-IVD) Meaningfu
Slide 25: Reproductive Health Value Creation Focus: Democratizing NIPT
REPRODUCTIVE HEALTH VALUE CREATION FOCUS Strengthen Democratizing Driving our global presence, with the end Core Right to Win goal of NIPT for every woman NIPT Favorable Macros for Future Growth Expanded insurance Maximize Growth Accelerators coverage in the US Increased need for affordable NIPT tes
Slide 26: Putting It All Together: Scaling Our Approach for Maximized Value Creation
PUTTING IT ALL TOGETHER: SCALING OUR APPROACH FOR MAXIMIZED VALUE CREATION SAM PKI Dx Revenue Mix CAGR* vs Market (2020e) Value Creation Focus (‘18-’19) (‘21+) ✓ Strong brand equity and scientific expertise in IVD ImmunoDx ✓ Expand technology offering into low- and high-throughput markets 7-9% + (51
Slide 27: Long-Term Financial Outlook
LONG-TERM FINANCIAL OUTLOOK VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life 3 Science Event Strengthen Core Confidence in December 202
Slide 28: Positioned for More Consistent and Faster Growth
POSITIONED FOR MORE CONSISTENT AND FASTER GROWTH Core PKI (excluding COVID-19) Pathway to $4.0B+ in 2023 3-Year Organic Growth Forecast +400M $4.0B+ DAS Dx +350M $1.7B $1.0B✓ >$2.5B Food +550M 6% additional 4-6% AG Total Core capital for ✓ $250M Applied M&A PKI 2-4% $2.7B revenue IDx 10%+ from 2020
Slide 29: With a Clear Path for Margin Expansion
WITH A CLEAR PATH FOR MARGIN EXPANSION Operating Profit Margins Diagnostics Drivers bps improvement ✓ Euroimmun gross margin 23%+ +75 20.7%✓ COVID-19 recurring increase Per year* PKI ✓ Volume leverage 30%+ Dx 27.8% DAS Drivers ✓ Analytical instruments 22%+ DAS 19.4% ✓ Services ✓ Volume leverage & mi
Slide 30: Including Significant Capital Deployment Flexibility
INCLUDING SIGNIFICANT CAPITAL DEPLOYMENT FLEXIBILITY Capital Deployed ($B) M&A & Investments (~80%) 4.0 • Prior success: $2.5B investments +2x/yr generates $0.5B+ (18%) of PKI PKI 3.3 revenue • Future focus: Diagnostics & Life Sciences, seed investments in transformative early-stage technology 3.2 M
Slide 31: Putting It All Together: By 2023, We Will Have...
PUTTING IT ALL TOGETHER: BY 2023, WE WILL HAVE … SCALE PERFORMANCE INVESTMENT $4B+ >$6.50 ~$4B Adjusted Deployable Revenue EPS Capital … driven by a focused value creation framework 31PUTTING IT ALL TOGETHER: BY 2023, WE WILL HAVE … SCALE PERFORMANCE INVESTMENT $4B+ >$6.50 ~$4B Adjusted Deployable R
Slide 32: PerkinElmer Will Host an Analyst Day in Q2 2021
PerkinElmer will host an ANALYST DAY in Q2 2021 32 32PerkinElmer will host an ANALYST DAY in Q2 2021 32 32
Slide 33: Innovating for a Healthier World
Innovating for a healthier world ONE MISSION Countless Opportunities 33Innovating for a healthier world ONE MISSION Countless Opportunities 33 Exhibit 99.2